Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), by Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region - Global Trends and Forecast till 2025

  • Published On : Feb 2018 |
  • Pages : 175 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Hereditary Angioedema Market – Efficient Disease Management for Orphan Disease

Hereditary angioedema (HAE) is a rare disorder related with the immune system. The life-threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE cases result from a spontaneous mutation of the C1-inhibitor gene at conception.

The global hereditary angioedema market was valued at US$ 1,563.7 million in 2016 and is expected to witness a robust CAGR of 9.1% over the forecast period (2017 - 2025).

Figure 1. Global Hereditary Angioedema Market (US$ Mn), by Region, 2016

hereditary angioedema market

Source: Coherent Market Insights (2018)

Increasing prevalence and rising awareness of hereditary angioedema to augment market growth

The increasing number of hereditary angioedema cases and the hereditary nature giving the disease an ability to pass the defective gene to the future generations is expected to propel market growth. According to the survey by International Hereditary Angioedema Organization (HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people, meaning that around a quarter million people suffer globally from this rare and life threatening deficiency condition. Also, according to National Association for Rare Disorders, 2016, the risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child. North America dominates the hereditary angioedema market, owing to the higher number of drugs approved in the regions, presence of major manufacturers and the presence of various organizations serving HAE patients. In 2017, the U.S. Food and Drug Administration (FDA) approved Haegarda (C1-esterase inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent HAE attacks in adolescent and adult patients. However, the rare occurrence of the disease make it difficult for efficient diagnosis and either opt for alternative therapies to control the disease, thus accounting to be the major factors restraining the market growth.

Increasing support from non-profit organizations towards intensive research is expected to accelerate the market

The organizations are focusing on increasing global HAE awareness by educating and empowering patient, providing access to suitable therapy/treatment. The organizations are also working towards intensive research to find a cure. For instance, the non-profit organization named HAEi is dedicated towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access to reimbursement of the HAE therapies, enabling lifelong health for the global patients. The organization also initiated the Global Access Program (HAEi GAP) in 2015, to provide the access to the approved HAE medications in countries where modern therapies are otherwise unavailable. Moreover, the non-profit organization- US Hereditary Angioedema Association is committed to advance and conduct clinical research designed to improve the lives of HAE patients. The major players operating the global hereditary angioedema market include CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies and Attune Pharmaceuticals, Inc.

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.

Market Dynamics

The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.

Key features of the study:

  • This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics
  • The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

  • Global Hereditary Angioedema Market, By Drug Class:
    • C1 Esterase Inhibitor
    • Kallikrein Inhibitor
    • Bradykinin Receptor
    • Attenuated Androgens
    • Others
  • Global Hereditary Angioedema Market, By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
  • Global Hereditary Angioedema Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Hereditary Angioedema Market, By Geography:
    • North America
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • C1 Esterase Inhibitor
        • Kallikrein Inhibitor
        • Bradykinin Receptor
        • Attenuated Androgens
        • Others
      • By Route of Administration:
        • Subcutaneous
        • Intravenous
        • Oral
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • CSL Behring*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Shire Plc.
    • Pharming Healthcare, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Attune Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Pipeline Analysis
    • Regulatory Guidelines
    • Epidemiology
  4. Global Hereditary Angioedema Market, By Drug Class, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • C1 Esterase Inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Kallikrein Inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Bradykinin Receptor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Attenuated Androgens
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  5. Global Hereditary Angioedema Market, By Route of Administration, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Subcutaneous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  6. Global Hereditary Angioedema Market, By Distribution Channel, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • e-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  7. Global Hereditary Angioedema Market, By Region, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2025
    • North America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • CSL Behring*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Shire Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pharming Healthcare, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • BioCryst Pharmaceuticals, Inc.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Ionis Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Attune Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Arrowhead Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Adverum Biotechnologies
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.